Iovance Biotherapeutics Appoints Corleen Roche as Chief Financial OfficerSAN CARLOS, Calif., July 15, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (
NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced the appointment of Corleen Roche as Chief Financial Officer (CFO), effective August 6th, 2025.
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance Biotherapeutics
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Iovance Biotherapeutics, Inc. (“Iovance” or the “Company”) (
NASDAQ: IOVA) and reminds investors of the July 14, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
FINAL IOVANCE DEADLINE ALERT: Bragar Eagel & Squire, P.C. Urges Investors in Iovance Biotheapeutics, Inc. (IOVA) to Inquire About Their Rights in Class Action LawsuitBragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Iovance (IOVA) To Contact Him Directly To Discuss Their Options
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Iovance Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - IOVANEW YORK, July 14, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Iovance Biotherapeutics, Inc. (“Iovance” or the “Company”) (
NASDAQ: IOVA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
Class Action Filed Against Iovance Biotherapeutics, Inc. (IOVA) - July 14, 2025 Deadline to Join - Contact Levi & KorsinskySearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Class Action Filed Against Iovance Biotherapeutics, Inc. (IOVA) - July 14, 2025 Deadline to Join - Contact Levi & KorsinskyNEW YORK - July 14, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (
NASDAQ: IOVA) of a class action securities lawsuit.
IOVA Deadline: Rosen Law Firm Urges Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of purchasers of Iovance Biotherapeutics, Inc. (
NASDAQ: IOVA) securities between May 9, 2024 and May 8, 2025. Iovance is a commercial stage biopharmaceutical company.
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance BiotherapeuticsFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Iovance To Contact Him Directly To Discuss Their Options
July 14, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against IOVASearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
July 14, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against IOVANEW YORK - July 11, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (
NASDAQ: IOVA) of a class action securities lawsuit.
Iovance Biotherapeutics Appoints Marc R. Theoret, M.D. as Senior Vice President, Regulatory StrategySAN CARLOS, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (
NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced the appointment of Marc. R Theoret, M.D. to assume the newly created position of Senior Vice President, Regulatory Strategy, where he will focus on clinical regulatory strategy for Iovance’s pipeline. Effective immediately, Dr. Theoret will report to Dr. Raj K. Puri, M.D., Ph.D., Chief Regulatory Officer.
Investors in Iovance Biotherapeutics, Inc. Should Contact Levi & Korsinsky Before July 14, 2025 to Discuss Your Rights - IOVASearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Investors in Iovance Biotherapeutics, Inc. Should Contact Levi & Korsinsky Before July 14, 2025 to Discuss Your Rights - IOVANEW YORK - July 10, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (
NASDAQ: IOVA) of a class action securities lawsuit.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Iovance Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - IOVANEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Iovance Biotherapeutics, Inc. (“Iovance” or the “Company”) (
NASDAQ: IOVA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
Iovance Biotherapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before July 14, 2025 to Discuss Your Rights - IOVANEW YORK - July 9, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (
NASDAQ: IOVA) of a class action securities lawsuit.
IOVA LAWSUIT ALERT: Levi & Korsinsky Notifies Iovance Biotherapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineNEW YORK - July 8, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (
NASDAQ: IOVA) of a class action securities lawsuit.
IOVA LAWSUIT ALERT: Levi & Korsinsky Notifies Iovance Biotherapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Krispy Kreme, Strategy Incorporated, Organon, and Iovance and Encourages Investors to Contact the FirmNEW YORK, July 07, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Krispy Kreme, Inc. (
NASDAQ:DNUT), Strategy Incorporated (
NASDAQ:MSTR), Organon & Co. (
NYSE:OGN), and Iovance Biotherapeutics, Inc. (
NASDAQ:IOVA). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 14, 2025 in Iovance Lawsuit - IOVASearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 14, 2025 in Iovance Lawsuit - IOVANEW YORK - July 7, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (
NASDAQ: IOVA) of a class action securities lawsuit.
